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Abstract
Background: ECRG4 has been shown to be a candidate tumor suppressor in several tumors, but its role in glioma 
remains poorly understood. In this study, we examined the mRNA expression of ECRG4 and investigated its biological 
role in glioma cells.
Methods: Real-time PCR was used to examine expression of ECRG4 in gliomas and their matched brain tissues. The 
effect of ECRG4 expression on cell proliferation, invasion, and migration was investigated in human U251 glioma cells. 
Finally, the regulation of transcription factor NF-kB by ECRG4 was evaluated by western blotting.
Results: Of the 10 paired samples analyzed, 9 glioma tissues displayed the decreased expression of ECRG4 compared 
to matched normal brain tissues. Cells transfected with ECRG4 showed significantly decreased cell proliferation as 
evaluated by MTT and colony formation assays. Furthermore, overexpression inhibited cell migration and invasion in 
transwell and Boyden chamber experiments and retarded the cell cycle progression from G1 to S phase by FACSCaliber 
cytometry. Protein levels of nuclear transcription factor NF-kB, which is involved in cell proliferation, inversely correlated 
with ECRG4 expression.
Conclusion: Our data suggest that ECRG4 serves as a tumor suppressor in glioma.
Introduction
Glioma is the most common and aggressive form of brain
tumors that affects adults. Despite advances in surgical
and clinical neuro-oncology, malignant glioma prognosis
remains poor due to its diffuse and invasive nature. To
date, the molecular pathogenesis of glioma is still unclear.
As a result, a major research effort has been directed at
identification of specific genes which might play impor-
tant roles in glioma carcinogenesis.
The ECRG4 gene [GenBank accession no.AF325503]
was initially identified and cloned by Bi et al[1,2] by com-
paring differential gene expression between human nor-
mal esophageal epithelia and ESCCs from high incidence
families in Linxian County of Northern China. Further,
this group [3,4] and Mori [5] found that ECRG4 expres-
sion was significantly decreased in ESCC tissues and cell
lines compared to normal adult esophageal epithelia.
Hypermethylation of CpG islands of gene promoter
often causes transcriptional silencing of genes, including
tumor suppressor genes [6-10]. Previous studies reported
promoter hypermethylation and reduced expression of
ECRG4 in advanced esophageal, prostate carcinomas,
colorectal carcinoma, and glioma[3,11,12] Together with
a study in esophageal cancer cell lines[4], these reports
suggest that ECRG4 may play a tumor suppressor role in
certain cancers including glioma. However, the function
and mechanisms mediated by the loss of ECRG4 expres-
sion in glioma remains unclear.
In the present study, we examined the expression of
ECRG4 in gliomas and explored its role as a tumor-sup-
pressor gene in glioma cells in vitro. We provided a pre-
liminary molecular mechanism of ECRG4-mediated
suppression of glioma cell growth.
Materials and methods
Cells
U251 human glioma cells were cultured in RPMI1640
medium (HyClone Inc, USA) supplemented with 10%
new calf bovine serum (NCBS) (PAA Laboratories, Inc,
Austria) in a 37°C, 5% CO2 incubator.* Correspondence: yanghongfa_science@163.com2 Department of Neurosurgery, the First Affiliated Hospital of Jilin University, 
130021, PR China
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Ten (10) fresh paired gliomas and adjacent normal brain
were collected from the first Affiliated Hospital of Jilin
University, China, at the time of first resections before
any therapy. All fresh samples were immediately pre-
served in liquid nitrogen. Prior consent from patients and
approval from the Ethics Committees of this hospital
were obtained for use of these clinical materials for
research purposes. All specimens had confirmed patho-
logical diagnosis.
Real-time PCR
Real-time PCR was performed to measure the expression
of ECRG4 mRNA using SYBR Premix Ex Taq (Takara,
Japan) with an Mx3000P real-time PCR system (Strata-
gene, La Jolla, CA, USA) as described previously [13].
The sequence for sense primer was 5'- TTCCTTG-
GCAGCCTGAAGCG-3', and for antisense primer was
5'- GGCTCCATGCCTAAAGCCGT-3'. GAPDH gene
was used as an internal control using the sense primer 5'-
GCACCGTCAAGGCTGAGAAC-3' and antisense
primer 5'-TGGTGAAGACGCCAGTGGA-3'.
Construction of pECRG4-EGFP-N1 vector and 
Establishment of glioma U251 cell line stably expressing 
ECRG4
The ECRG4 open reading frame was amplified from
cDNA clone IMAGE:5260075 using the forward primer
5'- ATACGTCGACATGGCTGCCTCCCCCGCG-3' and
the reverse primer 5'-CGATGGATCCGTAGTCATCG-
TAGTTGACGCT-3' introducing SalI and BamHI restric-
tion endonuclease sites. ECRG4 cDNA digested with SalI
and BamHI was cloned into a pEGFP-N1 eukaryotic
expression vector. The resulting vector was transfected
into U251 cells using lipofectamine 2000 (Invitrogen,
Carlsbad, CA). An "empty" vector pEGFP-N1 was utilized
as a negative control. After 24 to 48 h, the transient trans-
fection efficiency was determined using an Olympus flu-
orescence microscope. Cells were then passaged at
appropriate ratios in six-well plates. The next day, cells
were cultured in the presence of 1,000 to 2,000 μg/mL
G418 (Life Technology) increased in a stepwise manner
for 14 days for selection of highly expressing GFP cells.
Total RNA of all single cell clones was isolated and quan-
titative RT-PCR performed to detect the mRNA level of
ECRG4 as described above. Each sample was measured at
least three times.
Western blot analysis
Approximately 5 × 106 U251 cells were lysed in RIPA Buf-
fer and total protein concentration determined with BCA
assay (Beyotime Inc, China). Total protein (30 μg) was
loaded onto 12% SDS-PAGE gel. Antibodies used for
Western blot analysis included: polyclonal anti-GFP anti-
body (Abcam, MA, USA, 1:400), NF-kB (Abcam, MA,
USA, 1:400), and anti-ACTB antibody (Santa Cruz, USA,
1:400), and HRP-conjugated anti-rabbit secondary anti-
body (Zhongshan Inc, 1:2000). Each experiment was per-
formed in triplicate.
Cell proliferation analysis
Cell growth was determined by MTT assay (Sigma, USA).
Briefly, 1 × 103 cells were seeded into 96-well plate in qua-
druplicate for each condition. Approximately 72 h later,
MTT reagent was added to each well at 5 mg/mL in 20 μL
and incubated for another 4 h. The formazan crystals
formed by viable cells were then solubilized in DMSO
and measured at 490 nm for the absorbance (A) values.
Each experiment was performed in triplicate.
Plate colony formation assay
Approximately 100 cells were added to each well of a six-
well culture plate. After incubation at 37°C for 15 days,
cells were washed twice with PBS and stained with
Giemsa solution. The number of colonies containing ≥50
cells was counted under a microscope [plate clone forma-
tion efficiency = (number of colonies/number of cells
inoculated) × 100%]. Each experiment was performed in
triplicate.
Cell Cycle analysis
Cells grown in regular growth or serum-free media for 36
h were collected, fixed in methanol and stained with PBS
containing 10 μg/mL propidium iodide and 0.5mg/mL
RNase A for 15 min at 37°C. The DNA content of labeled
cells was acquired using FACS Caliber cytometry (BD
Biosciences). Each experiment was performed in tripli-
cate.
In Vitro migration and Invasion assay
Cells growing in the log phase were treated with trypsin
and re-suspended as single-cell solutions. A total of 1 ×
105 cells were seeded on a fibronectin-coated polycarbon-
ate membrane insert in a transwell apparatus (Corning
Inc, USA). In the lower chamber, 600 μl RPMI 1652 with
10% NBCS added as a chemoattractant. After the cells
were incubated for 14 h at 37°C and 5% CO2 incubator,
the insert was washed with PBS, and cells on the top sur-
face of the insert were removed by a cotton swab. The
matrigel invasion assay was similar to the cell migration
assay, except the transwell membrane was precoated with
ECMatrix and the cells were incubated for 16 hours at
37°C and 5% CO2 incubator. Cells adhering to the lower
surface were fixed by methanol, stained by Giemsa and
counted under a microscope in five predetermined fields
(×200). All assays were independently repeated at least
three times.
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Downregulated expression of ECRG4 in Gliomas
In order to assess the role of ECRG4 in glioma, we per-
formed real-time PCR to measure the expression of
ECRG4 mRNA transcripts in 10 paired gliomas and their
adjacent brain tissues. As shown in Figure 1A, 9 glioma
tissues showed markedly decreased expression (>2-fold
change) of ECRG4 compared to their matched normal
tissues.
Overexpression of ECRG4 in glioma U251 cell line
To study the biological functions of ECRG4, we intro-
duced ECRG4 into U251 glioma cells using a pEGFP-N1
eucaryotic expression vector containing ECRG4 gene.
Seven stably transfected cell clones were obtained. Real-
time PCR identified two cell clones(ECRG4-5,-7) with the
highest mRNA expression of ECRG4(Figure 2A). Further,
Western blotting assay with a GFP antibody showed that
ECRG4-GFP fusion protein in two cell clones was highly
expressed, compared to control clone cells (Figure 2B).
ECRG4 inhibits cell proliferation in vitro
To analyze the function of ECRG4, we studied the rate of
cell proliferation of ECRG4-expressing ECRG4-5 and -7
cells. The growth curves determined by an MTT assay
showed that ECRG4 significantly inhibited cell prolifera-
tion of these two lines of cells compared to parental line
U251 and Control clone cells (Figure 3A). The results
from a colony formation assay showed that ECRG4-over-
expressing ECRG4-5 and -7 cells formed significantly less
colonies than Control clone cells (P < 0.001 for both cell
types) (Figure 3B), suggesting an inhibitory effect of
ECRG4 on anchorage-dependent growth of glioma cells.
ECRG4 suppressed cell migration and invasion
To measure the effect of ECRG4 on cell migration,
ECRG4-expressing ECRG4-5 and -7 cells were cultured
on a transwell apparatus. After 12-h incubation, cell
migration was significantly decreased in both ECRG4-
overexpressed cell groups compared to the parental U251
cells and the ECRG4-negative control cells (for both P <
0.001) (Figure 4A). Using a Boyden chamber coated with
matrigel, we measured cell invasion after 16-h incuba-
tion. Compared with the negative control cells, ECRG4-
expressing -5 and -7 cells both showed significantly
decreased invasiveness (for both P < 0.001) (Fig 4.B).
Inhibition of cell cycle by ECRG4
To detect the effect of ECRG4 on the cell cycle, we mea-
sured cell cycle distribution in ECRG4-expressing -5 and
-7 cells. In these lines the S-phase population was mark-
edly decreased while the G1 population significantly
increased in both two cell lines compared to the Ctr-vec-
tor cells and U251 cells (P < 0.001). Neither cell line had
significant changes in the G2 population (Figure
4C)(Table 1).
Figure 1 The reduced expression levels of ECRG4 mRNA in glioma. A. ECRG4 mRNA level was markedly downregualted in glioma tissue compar-
ing to their matched normal brain tissues. (T: Tumor; N: Normal tissue).
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We were further interested in exploring the molecular
mechanism of ECRG4 tumor-suppression in glioma. We
found that restoration of ECRG4 expression in glioma
U251 cells inhibited expression of transcription factor
NF-κB (Figure 5A). This suggested that ECRG4 may be
involved in NF-κB pathway in glioma.
Discussion
Malignant glioma is a highly invasive and clinically chal-
lenging tumor of the central nervous system, and its
molecular basis remains poorly understood. We became
interested in ECRG4 because it is normally expressed in
the brain yet was found to be downregulated in gliomas.
Northern blot assays revealed that ECRG4 is also
expressed in other tissues including heart, placenta, lung,
liver, skeletal muscle, kidney and pancreas [14]. Further,
ECRG4 promoter hypermethylation has been attributed
to decreased expression in esophageal, prostatic, and col-
orectal cancers. Together these results suggest that
ECRG4 might play a suppressive role in tumor pathogen-
esis. ECRG4 contains a 772-bp full-length cDNA frag-
ment, and its open reading frame is 444bp encoding a
148-amino acid polypeptide with molecular weight of 17
kDa. ECRG4 gene is located at chromosome 2q12.2 and
contains 4 exons spanning about 12,500 bp.
In order to assess the role of ECRG4 in glioma, we first
performed real-time PCR to measure the expression of
ECRG4 mRNA transcripts in 10 paired gliomas and their
adjacent brain tissues. Similar to observations by Götze et
al [12], we found that ECRG4 expression was significantly
downregulated in 9 glioma tissues compared to their
matched normal tissues.
To examine whether ECRG4 plays a suppressive role in
glioma pathogenesis, we applied a gain-of-function
approach by introducing ECRG4 into cells to investigate
Figure 2 Restored expression of ECRG4 in glioma U251 cells. A. Real-time PCR analysis indicated the highest mRNA expression of ECRG4 in two 
cell clones pEGFP-ECRG4-5 and -7. B. Western blotting assay shows significantly increased protein expression of ECRG4 in pEGFP-ECRG4-5 and -7 com-
paring to Control cells. β-actin was used as the internal control.
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glioma cell line which exhibits relatively low expression
level of endogenous ECRG4 (data not shown) and pro-
vides a biologically relevant model for our study. U251
cells were transfected with ECRG4-GFP-expressing
eukaryotic vector followed by selection with G418. We
successfully established lines stably expressing ECRG4
protein at dramatically elevated levels compared to con-
trol cells. Subsequent functional studies demonstrated
that overexpression of ECRG4 led to significantly
reduced in vitro cell growth and G1/S transition block-
age. This is consistent with findings by Li et al [4,12] that
showed up-regulation of ECRG4 inhibited cell prolifera-
tion and cell cycle progression. This suggests that the bio-
logical functions of ECRG4 are not unique to a specific
cancer type, but likely common among multiple cancers.
Our study has revealed a novel function of ECRG4 in
suppression of glioma cell migration and invasion, impli-
cating its potential involvement in cancer metastasis.
This hypothesis should to be further validated in an in
vivo animal model. The observation that ECRG4 regu-
lates multiple cellular processes such as cell growth, cell
cycle, migration, and invasion in multiple cancers implies
it is an important therapeutic target for multiple human
cancers, including glioma.
NF-kB is a transcription factor that plays a key role in
carcinogenesis by controlling expression of several onco-
genes, tumor suppressor genes, growth factors and cell
adhesion molecules [15-17]. Li et al [4] previously
reported that ECRG4 overexpression could suppress
endogenous expression of the nuclear factor (NF-kB),
which may have contributed to inhibition of esophageal
cancer cell growth. Based on their finding, we speculated
ECRG4 might also be involved in glioma cell growth sup-
pression by regulating the NF- B pathway. Consistent
with this hypothesis, we showed that overexpression of
ECRG4 in glioma U251 cells markedly downregulated
expression of NF-κB by western blot. However, further
Figure 3 Overexpression of ECRG4 inhibted cell proliferation in vitro. A. The cell growth of parental U251 cells, Control-vector cells and pEGFP-
ECRG4-5 and -7 cells, were examined by MTT assay over a seven-day period. *P < 0.05, as compared to U251 and Control-vector cells. B. The cell growth 
of Control-vector cells and pEGFP-ECRG4-5 and -7 cells, were examined by plate colony formation assay. *P < 0.05, as compared to U251 and Control-
vector cells.
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ECRG4 in the NF-κB pathway within the context of
glioma.
In conclusion, we found that the ECRG4's role as a
tumor suppressor was supported by our observation that
its expression is decreased in glioma. Furthermore, we
applied gain-of-function approach to examine the biolog-
ical processes regulated by ECRG4 in glioma cells. We
demonstrated the functional importance of ECRG4 in
suppression of glioma cell growth, migration, and inva-
sion. Finally, we found that overexpression of ECRG4
could inhibit expression of NF-kB which may provide a
mechanism explaining ECRG4's role in controlling
glioma cell proliferation.
Figure 4 Increased ECRG4 expression inhibited cell migration, invasion and cell cycle progression. (A) Cell migration and (B)invasion capabil-
ities of Control-vector cells, pEGFP-ECRG4-5 and -7 cells, were examined using transwell assay and boyden chamber assay. Data were presented as 
mean ± SD for three independent experiments. *P < 0.05, as compared to Control-vector cells. C. Cell cycle in parental U251 cells, Control-vector cells 
and pEGFP-ECRG4-5 and -7 cells, was determined by FACS Caliber cytometry. *P < 0.05, as compared to parental U251 cells and Control-vector cells
Table 1: Overexpressed ECRG4 retarded cell cycle progression from G1 to S phase
Cells G1 S G2
pEGFP-ECRG4-5 64.93 ± 1.54 16.37 ± 1.12 18.7 ± 0.44
pEGFP-ECRG4-7 5.77 ± 1.34 15.23 ± 1.30 19.0 ± 0.44
Ctr-Vector 54.67 ± 1.27 26.13 ± 0.91 19.2 ± 2.05
U251 54.73 ± 0.86 25.87 ± 1.27 19.4 ± 1.77
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Figure 5 Overexpresed ECRG4 expression suppressed the expres-
sion of NF-kB protein. A. Protein expression of NF-kB was decreased 
in pEGFP-ECRG4-5 and -7 cells compared to Control-vector cells. Data 
were presented as mean ± SD. *P < 0.05.
